Malastad

Proguanil Hydrochloride and Atovaquone, the active ingredient in Malastad, is an antimalarial combination presented as an oral dosage form for oral use. It is used for prevention of malaria infection and treatment of acute uncomplicated malaria in adults and children as prescribed.

GNH USA supplies Malastad as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malastad, an antimalarial combination, is used in the prevention and treatment of malaria.

- Prevention of malaria infection: provides prophylactic protection for travelers and residents in endemic areas. - Treatment of acute uncomplicated malaria: clears Plasmodium parasites in patients with confirmed infection. - Chemoprophylaxis in high‑risk groups: reduces risk of malaria in individuals with increased exposure, such as military personnel.

Malastad may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Headache: transient headache. - Abdominal pain: discomfort in the stomach area. - Vomiting: occasional emesis.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: including rash, pruritus, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes or jaundice. - Blood dyscrasias: rare cases of neutropenia or agranulocytosis.

When prescribing Malastad, consider the following precautions to ensure safe use.

- Renal impairment: adjust use in patients with severe kidney dysfunction. - Hepatic disease: use with caution in liver impairment. - Pregnancy and lactation: safety not established; evaluate risk vs benefit. - Drug resistance: avoid monotherapy and ensure adherence to regimen. - Concomitant medications: review for potential interactions, especially with CYP450 substrates. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Malastad can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may increase atovaquone levels, risk of toxicity. - Antacids containing aluminum or magnesium: reduce atovaquone absorption, compromising efficacy.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism, lowering atovaquone concentrations. - Warfarin: proguanil may enhance anticoagulant effect, monitor INR. - Sulfonamides: additive risk of hypersensitivity reactions.